Navigation Links
Prometheus Announces New Chief Medical Officer
Date:11/14/2011

SAN DIEGO, Nov. 14, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the appointment of Dr. Peter Heseltine as Senior Vice President and Chief Medical Officer.

Dr. Heseltine joins Prometheus with almost 35 years of experience in the medical field.  He comes most recently from Beckman Coulter where he served as Vice President and Medical Director of Global Businesses since 2005. In this role he had corporate responsibility for medical input and oversight of in vitro diagnostics product design, development and life cycle management, including new cancer diagnostics, using immunoassay, flow cytometry and molecular technologies.

Prior to joining Beckman Coulter, Dr. Heseltine was Medical Director of Infectious Diseases at Nichols Institute Quest Diagnostics supervising high-volume, Molecular, Microbiology, Virology and Serology clinical laboratories. He formed a team of research scientists to develop new esoteric tests for infectious diseases under ISO 9001 standards and led a Six Sigma quality improvement program that introduced more than 50 new tests in four years.  Prior to joining Quest Diagnostics, Dr. Heseltine was a Chief Physician at Los Angeles County USC Hospital  and Professor of Medicine at the University of Southern California.  Dr. Heseltine received his medical training at Trinity College, Dublin University and postgraduate training at Yale University, the University of California, Los Angeles and the U. S. Centers for Disease Control. He is Board certified in Internal Medicine and Infectious Diseases. Dr. Heseltine is a Fellow of the American College of Physicians, Fellow of the National Academy of Clinical Biochemistry and a Fellow of the Infectious Diseases Society of America. He maintains a position as Clinical Professor of Medicine at the University of California, Irvine.

"Peter brings a wealth of medical, clinical and product development experience which will be very valuable during this important stage of our company's growth," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "He is a welcome addition to our senior management team and will play a key role in planning and executing our core strategy as we continue to build on our success."

About Prometheus

Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus became part of Nestle Health Science in July 2011.  Prometheus' corporate offices are located in San Diego, California. For more information about Prometheus, please visit www.prometheuslabs.com.

About Nestle Health Science

Nestle Health Science, a fully-owned subsidiary of Nestle S.A., is operational since January 1, 2011 and has worldwide headquarters in Lutry, Switzerland. Nestle Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. For more information about Nestle Health Science, please visit www.nestlehealthscience.com.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
4. Prometheus Launches ProOnc Dx Cancer Diagnostics
5. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
8. Prometheus Highlights Record Performance in 2010
9. Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®
10. Prometheus Announces Agreement to be Acquired by Nestle Health Science
11. Prometheus and the Medco Research Institute® to Evaluate the Use of Prometheus Thiopurine Metabolite Testing for Optimizing Treatment of Inflammatory Bowel Disease Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO), is ... residents. Naloxone is available without ... retail pharmacy, G-3320 Beecher Road. ... Drug Administration, is intended to block or reverse the ... loss of consciousness. The medication is often carried by ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million and ... operations Second-quarter 2017 Branded ... Second-quarter 2017 Sterile Injectables ... Second-quarter 2017 adjusted diluted earnings per ... $0.93 Second-quarter 2017 reported ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... ... “Our Mountains to Climb: A Journey of Love and Faith Through Trials”: ... the faith they shared to overcome struggles in life. “Our Mountains to Climb: A ... J. Corcoran, a retired teacher and happily married since 1999; the author’s personal experiences ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... marketers of high-quality anti-aging skincare solutions, recently announced the launch of ... products are an affordable, yet effective alternative to expensive plastic surgery or in-patient ...
(Date:8/17/2017)... ... August 17, 2017 , ... Riccobene Associates Family Dentistry, ... Goldsboro, NC to its family of practices. Residents of Goldsboro will be able ... 15, 2017. , Riccobene Associates Family Dentistry, founded by Dr. Michael Riccobene ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... of three years for its residential drug and alcohol detox program. This accreditation ... organization and shows the organization’s substantial conformance to the CARF standards. , Behavioral ...
(Date:8/17/2017)... ... August 17, 2017 , ... The 2017 Integrated Delivery ... systems to interact with their GPO and supplier partners. This year, Winifred Hayes, ... System Director of Clinical Value Analytics, have been invited to present “Episode-based Reimbursement ...
Breaking Medicine News(10 mins):